RESILIENCE hilft Ihnen, Krebs mit einem starken Herzen zu überleben

Warum NON-HODGKIN Lymphom

Lymphoma patients are treated with a very homogeneous combination chemotherapy that includes anthracyclines.

This is an ideal setting for a controlled trial in order to reduce the chances of confounders. NHL patients are especially vulnerable to anthracycline-induced cardiotoxicity. Mean age of NHL diagnosis is in the eight decade of life, a time where cardiovascular comorbidities are frequent, increasing the likelihood of post-therapy heart failure. Another important rationale for choosing this cancer type as a target of this project is that there is a balance in the incidence of NHL diagnoses across genders (60% male/40%female). There is no conclusive information about gender differences in cancer therapy-induced cardiotoxicity. One main reason for this lack of information is that most of the studies evaluating the incidence of cardiotoxicity have been done in breast cancer patients, a malignancy with a very low representation of male patients. Our aim is to extend the results of the project beyond NHL to all cancer patients treated with anthracyclines

Logotipo Resilience

Sind Sie ein Patient, der an RESILIENCE teilnimmt? Hier finden Sie nützliche Informationen zu den Einzelheiten Ihrer Teilnahme und speziell auf Sie zugeschnittene Aktivitäten. Sie können auch mit RESILIENCE-Forschern in Kontakt treten.

Verwenden Sie unser kurzes Formular, um uns zu kontaktieren. Unser Team wird Ihre Anfrage lesen und so schnell wie möglich antworten.